ArticleInternational journal of pharmaceutics: X2026
Baicalein solid dispersion prepared by solvent evaporation enhances oral bioavailability and alleviates ulcerative colitis.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baicalein (BAC) is a flavonoid compound known for its effectiveness in treating ulcerative colitis (UC). However, its clinical application is limited by poor water solubility, low stability, and low oral bioavailability. In this study, a baicalein solid dispersion (BAC-SD) was prepared using Polyvinylpyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) as carriers via the solvent evaporation method. Scanning Electron Microscope (SEM), Powder X-Ray Diffraction 6000 diffractometer (PXRD), Differential Scanning Calorimetry (DSC), and Fourier Transform Infrared Spectroscopy (FT-IR) analyses confirmed the transition of BAC from a crystalline to an amorphous state. This transformation significantly improved the solubility, dissolution rate, and permeability of BAC. The in vitro dissolution results showed that the cumulative dissolution rate of BAC-SD reached 86.86% at 240 min, representing a 10.09-fold increase in solubility compared to BAC. In Caco-2 and MDCK cell models, the apparent permeability coefficient (Papp) of BAC-SD increased by 2.7- and 3.1-fold, respectively. Pharmacokinetic studies in rats demonstrated that the relative bioavailability of BAC-SD was 236.4% compared to BAC. In the DSS-induced UC mouse model, BAC-SD treatment alleviated UC by increasing colon length, improving pathological damage, and reducing both the Disease Activity Index (DAI) score and levels of inflammatory factors, including TNF-α, IL-1β, and IL-6. In conclusion, we successfully prepared BAC-SD and demonstrated that its therapeutic effect on UC is achieved by enhancing solubility, permeability, and oral bioavailability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.